Bumetanide oral - Neurochlore

Drug Profile

Bumetanide oral - Neurochlore

Alternative Names: Bumetanide oral liquid - Neurochlore

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurochlore
  • Class Antihypertensives; Benzoic acids; Heart failure therapies; Sulfonamides
  • Mechanism of Action Ion pump modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Autistic disorder

Most Recent Events

  • 05 Apr 2017 Chemical structure information added
  • 14 Mar 2017 Bumetanide oral licensed to Servier in Europe
  • 14 Mar 2017 Servier and Neurochlore plan to file a marketing authorization for bumetanide oral in Autistic disorder (In children, In adolescents) (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top